Showing 61 - 70 of 108,144
To overcome the problem of insufficient research and development (R&D) on vaccines for diseases concentrated in low-income countries, sponsors could commit to purchase viable vaccines if and when they are developed. One or more sponsors would commit to a minimum price that would be paid per...
Persistent link: https://www.econbiz.de/10012467396
The COVID-19 pandemic has highlighted both the strengths and weaknesses of national, regional, and global vaccine research and development (R&D) systems. Translating public and private R&D efforts into effective vaccines in a timely manner requires not only sufficient financial and scientific...
Persistent link: https://www.econbiz.de/10013417528
There have been many important innovations in the landscape of vaccine development for neglected and emerging infectious diseases, such as the launch of public-private product development partnerships (PDPs). However, there is still a gap in funding the development of such vaccines, especially...
Persistent link: https://www.econbiz.de/10013461152
What is the return to COVID-19 vaccine innovation? This paper seeks to quantify both private and social returns, using available data on commercialized vaccines and certain assumptions about the pandemic’s epidemiological path as well as the economic costs of containment measures. The...
Persistent link: https://www.econbiz.de/10014357767
To overcome the problem of insufficient research and development (R&D) on vaccines for diseases concentrated in low-income countries, sponsors could commit to purchase viable vaccines if and when they are developed. One or more sponsors would commit to a minimum price that would be paid per...
Persistent link: https://www.econbiz.de/10014065925
To overcome the problem of insufficient research and development (R&D) on vaccines for diseases concentrated in low-income countries, sponsors could commit to purchase viable vaccines if and when they are developed. One or more sponsors would commit to a minimum price that would be paid per...
Persistent link: https://www.econbiz.de/10013229370
Indonesian waters are known as mega-diversity resource which can produce many chemical compounds. These compounds have been identified could be a sustainable source for novel drugs, especially for the usage of pharmaceutical. Up to 2007, at least 77 new compounds are from 14 sponges and 19 new...
Persistent link: https://www.econbiz.de/10011447626
Persistent link: https://www.econbiz.de/10011430453
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875
Patent-based measures are frequently used as indicators in empirical research on innovation and technology as well as on firms' strategies and organizational choices to characterize inventions or, more generally, innovative activities and the technological capabilities of organizations. A clear...
Persistent link: https://www.econbiz.de/10010258420